OncoMatch/Clinical Trials/NCT07357519
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
Is NCT07357519 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including LNTH2403 Phase 1 dose and Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). for relapsed / refractory osteosarcoma.
Treatment: LNTH2403 Phase 1 dose · Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). — This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Osteosarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: chemotherapy — neoadjuvant / perioperative systemic therapy included
Progression following at least one course of chemotherapy, which includes neoadjuvant / perioperative systemic therapy.
Lab requirements
Blood counts
Kidney function
Liver function
Organ Function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07357519 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages